Board Change • Jun 20
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Director Krister Pantzar Huth is the most experienced director on the board, commencing their role in 2017. CEO & Independent Director Jan Bengtsson was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. New Risk • Sep 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr10.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr10.0m free cash flow). Earnings have declined by 59% per year over the past 5 years. Market cap is less than US$10m (kr75.4m market cap, or US$8.01m). Reported Earnings • Aug 12
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: kr71.7m (down 21% from 2Q 2024). Net loss: kr514.0k (loss narrowed 99% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 45% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 27
First quarter 2025 earnings released: kr0.034 loss per share (vs kr0.70 loss in 1Q 2024) First quarter 2025 results: kr0.034 loss per share (improved from kr0.70 loss in 1Q 2024). Revenue: kr78.5m (down 22% from 1Q 2024). Net loss: kr847.0k (loss narrowed 87% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 15 percentage points per year, which is a significant difference in performance. Announcement • Mar 19
NGS Group AB (publ), Annual General Meeting, Apr 24, 2025 NGS Group AB (publ), Annual General Meeting, Apr 24, 2025, at 14:00 W. Europe Standard Time. Location: kungsgatan 12, stockholm Sweden Reported Earnings • Nov 18
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr86.3m (down 27% from 3Q 2023). Net loss: kr2.52m (loss narrowed 98% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 23
Second quarter 2024 earnings released: kr3.22 loss per share (vs kr0.52 loss in 2Q 2023) Second quarter 2024 results: kr3.22 loss per share (further deteriorated from kr0.52 loss in 2Q 2023). Revenue: kr91.1m (down 30% from 2Q 2023). Net loss: kr62.9m (loss widened kr58.2m from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. New Risk • May 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 120% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 78% per year over the past 5 years. Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Market cap is less than US$10m (kr68.5m market cap, or US$6.42m). Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Johan Renvall was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 30
NGS Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 51.317549 million. NGS Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 51.317549 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 10,827,438
Price\Range: SEK 3.25
Security Name: Shares
Security Type: Common Stock
Securities Offered: 4,962,577
Price\Range: SEK 3.25
Transaction Features: Rights Offering; Subsequent Direct Listing Reported Earnings • Apr 28
First quarter 2024 earnings released: kr0.70 loss per share (vs kr0.30 loss in 1Q 2023) First quarter 2024 results: kr0.70 loss per share (further deteriorated from kr0.30 loss in 1Q 2023). Revenue: kr100.3m (down 29% from 1Q 2023). Net loss: kr6.29m (loss widened 128% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 03
Full year 2023 earnings released: kr13.94 loss per share (vs kr0.41 profit in FY 2022) Full year 2023 results: kr13.94 loss per share (down from kr0.41 profit in FY 2022). Revenue: kr499.6m (down 13% from FY 2022). Net loss: kr125.8m (down kr129.4m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Announcement • Mar 02
NGS Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.317549 million. NGS Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.317549 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 10,827,438
Price\Range: SEK 3.25
Security Name: Shares
Security Type: Common Stock
Securities Offered: 4,962,577
Price\Range: SEK 3.25
Transaction Features: Rights Offering; Subsequent Direct Listing New Risk • Nov 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (kr63.0m market cap, or US$6.03m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change). Reported Earnings • Nov 13
Third quarter 2023 earnings released: kr12.72 loss per share (vs kr0.58 loss in 3Q 2022) Third quarter 2023 results: kr12.72 loss per share (further deteriorated from kr0.58 loss in 3Q 2022). Revenue: kr118.0m (down 14% from 3Q 2022). Net loss: kr114.8m (loss widened kr109.5m from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 23
Second quarter 2023 earnings released: kr0.52 loss per share (vs kr0.54 profit in 2Q 2022) Second quarter 2023 results: kr0.52 loss per share (down from kr0.54 profit in 2Q 2022). Revenue: kr130.7m (down 9.8% from 2Q 2022). Net loss: kr4.72m (down 198% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Buying Opportunity • Jul 20
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 27%. The fair value is estimated to be kr11.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Jul 04
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be kr10.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Jun 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be kr10.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • May 01
First quarter 2023 earnings released: kr0.30 loss per share (vs kr0.45 profit in 1Q 2022) First quarter 2023 results: kr0.30 loss per share (down from kr0.45 profit in 1Q 2022). Revenue: kr141.3m (up 3.3% from 1Q 2022). Net loss: kr2.76m (down 168% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to kr11.45, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 13x in the Healthcare industry in Sweden. Total loss to shareholders of 15% over the past three years. Reported Earnings • Feb 12
Full year 2022 earnings released: EPS: kr0.41 (vs kr1.46 in FY 2021) Full year 2022 results: EPS: kr0.41 (down from kr1.46 in FY 2021). Revenue: kr571.2m (up 15% from FY 2021). Net income: kr3.67m (down 72% from FY 2021). Profit margin: 0.6% (down from 2.7% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment deteriorated over the past week After last week's 19% share price decline to kr11.20, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 15x in the Healthcare industry in Sweden. Total loss to shareholders of 38% over the past three years. Reported Earnings • Jul 21
Second quarter 2022 earnings released: EPS: kr0.54 (vs kr0.46 in 2Q 2021) Second quarter 2022 results: EPS: kr0.54 (up from kr0.46 in 2Q 2021). Revenue: kr144.9m (up 11% from 2Q 2021). Net income: kr4.83m (up 17% from 2Q 2021). Profit margin: 3.3% (up from 3.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 29
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: kr0.45 (up from kr0.071 in 1Q 2021). Revenue: kr136.8m (up 27% from 1Q 2021). Net income: kr4.04m (up kr3.40m from 1Q 2021). Profit margin: 3.0% (up from 0.6% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Apr 21
Upcoming dividend of kr0.50 per share Eligible shareholders must have bought the stock before 28 April 2022. Payment date: 04 May 2022. Trailing yield: 2.2%. Lower than top quartile of Swedish dividend payers (4.7%). Higher than average of industry peers (1.0%). Reported Earnings • Feb 11
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: kr1.46 (up from kr0.90 in FY 2020). Revenue: kr495.9m (up 15% from FY 2020). Net income: kr13.2m (up 62% from FY 2020). Profit margin: 2.7% (up from 1.9% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Reported Earnings • Nov 13
Third quarter 2021 earnings released: EPS kr0.46 (vs kr0.26 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr118.6m (up 14% from 3Q 2020). Net income: kr4.11m (up 77% from 3Q 2020). Profit margin: 3.5% (up from 2.2% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Reported Earnings • Jul 18
Second quarter 2021 earnings released: EPS kr0.46 (vs kr0.17 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr130.9m (up 23% from 2Q 2020). Net income: kr4.11m (up 170% from 2Q 2020). Profit margin: 3.1% (up from 1.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improved over the past week After last week's 22% share price gain to kr21.90, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 25x in the Healthcare industry in Sweden. Total loss to shareholders of 40% over the past three years. Announcement • Apr 28
An unknown buyer acquired a 27.3% stake in NGS Group AB (publ) (OM:NGS) from Charlotte Orvina Pantzar Huth. An unknown buyer acquired a 27.3% stake in NGS Group AB (publ) (OM:NGS) from Charlotte Orvina Pantzar Huth on April 26, 2021. As a part of transaction, Charlotte Orvina Pantzar Huth sold 2.461904 million shares of NGS Group AB. Post transaction, Charlotte Orvina Pantzar Huth will hold 2.404% stake representing 0.216904 million shares in NGS Group AB.
An unknown buyer completed the acquisition of a 27.3% stake in NGS Group AB (publ) (OM:NGS) from Charlotte Orvina Pantzar Huth on April 26, 2021. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS kr0.071 (vs kr0.18 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr108.2m (down 6.1% from 1Q 2020). Net income: kr642.0k (down 61% from 1Q 2020). Profit margin: 0.6% (down from 1.4% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 29
Full year 2020 earnings released: EPS kr0.90 (vs kr1.52 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr432.2m (down 21% from FY 2019). Net income: kr8.15m (down 41% from FY 2019). Profit margin: 1.9% (down from 2.5% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 13
Full year 2020 earnings released: EPS kr0.90 (vs kr1.52 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr432.2m (down 21% from FY 2019). Net income: kr8.15m (down 41% from FY 2019). Profit margin: 1.9% (down from 2.5% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 10
New 90-day high: kr16.40 The company is up 11% from its price of kr14.80 on 11 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 18% over the same period. Is New 90 Day High Low • Jan 22
New 90-day high: kr15.75 The company is up 2.0% from its price of kr15.45 on 23 October 2020. The Swedish market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 18% over the same period. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS kr0.26 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: kr103.6m (down 17% from 3Q 2019). Net income: kr2.33m (down 32% from 3Q 2019). Profit margin: 2.2% (down from 2.7% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 16
New 90-day high: kr15.40 The company is up 14% from its price of kr13.45 on 17 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 31% over the same period.